Pancreatic cancer research advances through cell communication studies and new drug access

Researchers are making advancements in understanding and treating pancreatic cancer, specifically pancreatic ductal adenocarcinoma (PDAC). Scientists from CONICET in Argentina have identified a communication mechanism used by PDAC cells to survive harsh conditions, such as nutrient and oxygen deprivation. The study, published in Scientific Reports, found that these cells release extracellular vesicles to signal other tumor cells to activate autophagy, a survival mechanism. This discovery may lead to new therapeutic approaches for a disease that is projected to become the second leading cause of cancer death globally by 2040.

In the United States, the Memorial Cancer Institute has become the first oncology program to obtain the investigational drug Daraxonrasib through the FDA’s Expanded Access Program. Daraxonrasib is being studied as a potential therapy for cancers driven by RAS mutations, which are common in pancreatic cancer. The drug aims to target molecular mechanisms that allow cancer cells to grow and survive. While still under clinical evaluation and not a guaranteed cure, the access provides a potential alternative for patients with life-threatening illnesses when other therapeutic options are exhausted.